This is a competing continuation to support five post-doctoral positions to provide rigorous research training for pulmonary physicians at the fellowship level and Ph.D. recipients with interests in lung disease. The ultimate goal is to develop pulmonary scientists in either basic or clinical research who can successfully continue their careers in academics or the pharmaceutical industry. After completion of clinical or Ph.D. training, all trainees begin a two year (minimum) period of virtually uninterrupted time for research training that begins with a one year period of mentored time in a basic research laboratory, supplemented by attendance at research conferences and seminars, as well as a variety of course work. In the second year of research, trainees choose to remain in a basic science laboratory or move to a more translational path under the supervision of one or more experienced clinical investigators. Coursework continues during this second year. Some trainees continue for a third year of research training. The program will continue to foster broad multidisciplinary approaches to research with strong ties to trainers outside of the Division, especially at the Wistar Institute. Over the past five years, two areas that have been developed are: 1) a """"""""translational/patient oriented research pathway"""""""" designed to allow some trainees to obtain basic science research experience, as well as complementary training in areas such as informatics, biostatistics, and clinical study trial design to allow them to conduct clinical (i.e. patient-oriented) and translational research. 2) a successful formalized mentoring system for all research trainees that incorporates a """"""""mentoring committee"""""""" for each trainee that meets every 6-9 months. Changes in this renewal are a 30% decrease in the number of positions requested, addition of selected faculty with unique training expertise, and an enlargement of the applicant pool by allowing Ph.D. researchers to apply. Continued efforts to increase minority recruitment are also planned.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Institutional National Research Service Award (T32)
Project #
5T32HL007586-25
Application #
7884600
Study Section
Special Emphasis Panel (ZHL1-CSR-J (O1))
Program Officer
Colombini-Hatch, Sandra
Project Start
1985-07-01
Project End
2011-06-30
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
25
Fiscal Year
2010
Total Cost
$150,359
Indirect Cost
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Zacharias, William J; Frank, David B; Zepp, Jarod A et al. (2018) Regeneration of the lung alveolus by an evolutionarily conserved epithelial progenitor. Nature 555:251-255
Dolinay, Tamás; Aonbangkhen, Chanat; Zacharias, William et al. (2018) Protein kinase R-like endoplasmatic reticulum kinase is a mediator of stretch in ventilator-induced lung injury. Respir Res 19:157
McGinniss, John E; Collman, Ronald G (2018) Of Mice and Men . . . and Microbes: Conclusions and Cautions from a Murine Study of the Lung Microbiome and Microbiome-Immune Interactions. Am J Respir Crit Care Med 198:419-422
Brenner, Jacob S; Bhamidipati, Kartik; Glassman, Patrick M et al. (2017) Mechanisms that determine nanocarrier targeting to healthy versus inflamed lung regions. Nanomedicine 13:1495-1506
Dolinay, Tamas; Himes, Blanca E; Shumyatcher, Maya et al. (2017) Integrated Stress Response Mediates Epithelial Injury in Mechanical Ventilation. Am J Respir Cell Mol Biol 57:193-203
Paris, Andrew J; Liu, Yuhong; Mei, Junjie et al. (2016) Neutrophils promote alveolar epithelial regeneration by enhancing type II pneumocyte proliferation in a model of acid-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol 311:L1062-L1075
Moon, Edmund K; Ranganathan, Raghuveer; Eruslanov, Evgeniy et al. (2016) Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer. Clin Cancer Res 22:436-47
Liu, Xiaojun; Ranganathan, Raghuveer; Jiang, Shuguang et al. (2016) A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. Cancer Res 76:1578-90
Thompson, Jeffrey C; Yee, Stephanie S; Troxel, Andrea B et al. (2016) Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA. Clin Cancer Res 22:5772-5782
Newick, Kheng; O'Brien, Shaun; Sun, Jing et al. (2016) Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization. Cancer Immunol Res 4:541-51

Showing the most recent 10 out of 32 publications